Viatris
VTRS · Nasdaq · United States
Share price · VTRS
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when VTRS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 6 Nov 2026+5.0%
- 6 Aug 2026-7.7%
- 7 May 2026+9.0%
- 2 Mar 2026+5.2%
Nothing announced by VTRS that day or the session before.
- 26 Feb 2026-5.2%
- 9 Feb 2026+6.7%
Nothing announced by VTRS that day or the session before.
- 13 Jan 2026+5.4%
Nothing announced by VTRS that day or the session before.
Share of unusual movement by asset
For each asset, the share of VTRS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(13 total)
| Target & Modality | |||
|---|---|---|---|
| Approved | 5-HT1B/1D receptorSmall molecule | Migraine | |
| Approved | NMDA receptor (glycine site, antagonist)Small molecule | EpilepsyLennox-Gastaut Syndrome Focal Onset Seizures | |
| Approved | α2δ subunit of voltage-gated calcium channelsSmall molecule | Epilepsy | |
| Approved | Glucocorticoid receptorSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
| Approved | AminosalicylateSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
| Approved | AminosalicylateSmall molecule | Inflammatory Bowel Disease Ulcerative Colitis | |
| Approved | Voltage-gated sodium channelsSmall molecule | Epilepsy | |
| Approved | Histamine H3 receptor (antagonist / inverse agonist)Small molecule | Myotonic Dystrophy Type 1NarcolepsyIdiopathic HypersomniaPrader-Willi Syndrome | |
| Approved | α2δ subunit of voltage-gated calcium channelsSmall molecule | EpilepsyDiabetic Peripheral Neuropathic PainFibromyalgia Diabetic Peripheral Neuropathy | |
Revefenacin(Yupelri) | Approved | Muscarinic receptors (antagonist)Small molecule | Chronic Obstructive Pulmonary Disease |
sildenafil(Revatio) | Approved | PDE5Small molecule | Pulmonary Arterial Hypertension |
| Approved | SGLT1/2 (dual)Small molecule | Heart FailureChronic Kidney DiseaseType 1 DiabetesHypertrophic Cardiomyopathy | |
| Approved | Dopamine D2 and serotonin 5-HT2A receptors (antagonist)Small molecule | SchizophreniaBipolar Disorder |
Upcoming events
(3 total)
Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.
2027 (2)
January 2027 (1)
What to watch
April 2027 (1)
What to watch
2030 (1)
August 2030 (1)
What to watch
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (16)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q3 | $3.7B | $232M | $1.8B | $325M$899M operating cash flow | report ↗ |
View 15 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $3.7B | $248M | $890M | —$382M operating cash flow | report ↗ |
| 2026-Q1 | $3.5B | $249M | $1.8B | —$388M operating cash flow | report ↗ |
| 2025-Q3 | $3.7B | $250M | $1.0B | —$745M operating cash flow | report ↗ |
| 2025-Q2 | $3.6B | $219M | $568M | —$220M operating cash flow | report ↗ |
| 2025-Q1 | $3.2B | $222M | $756M | —$536M operating cash flow | report ↗ |
| 2024-Q3 | $3.7B | $198M | $1.9B | —$827M operating cash flow | report ↗ |
| 2024-Q2 | $3.8B | $204M | $919M | —$379M operating cash flow | report ↗ |
| 2024-Q1 | $3.7B | $200M | $1.0B | —$615M operating cash flow | report ↗ |
| 2023-Q3 | $3.9B | $211M | $1.3B | —$834M operating cash flow | report ↗ |
| 2023-Q2 | $3.9B | $208M | $631M | —$515M operating cash flow | report ↗ |
| 2023-Q1 | $3.7B | $183M | $511M | —$971M operating cash flow | report ↗ |
| 2022-Q3 | $4.1B | $175M | $650M | —$869M operating cash flow | report ↗ |
| 2022-Q2 | $4.1B | $163M | $669M | —$803M operating cash flow | report ↗ |
| 2022-Q1 | $4.2B | $142M | $757M | —$1.1B operating cash flow | report ↗ |
| 2021-Q3 | $4.5B | $152M | $762M | —$1.1B operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $14.3B | — | $1.3B+ $41M short-term inv. | —$2.3B operating cash flow | report ↗ |
For full-year 2025, Viatris reported net sales of $14,250.4M, down 3.0% YoY, and total revenues of $14,299.9M, down 3% YoY. R&D expense was $965.9M, cash and equivalents stood at $1,348M, and the company recorded a U.S. GAAP net loss of $3,514.9M, including a $2.9B goodwill impairment.
Management guided 2026 total revenues to $14,450–$14,950M, adjusted EBITDA to $4,150–$4,450M, adjusted EPS to $2.33–$2.47, and free cash flow excluding transaction- and restructuring-related costs to $1,950–$2,350M. The company completed its enterprise-wide strategic review, expecting $650M in total cost savings with up to $250M reinvestment over three years and a workforce reduction of up to approximately 10%. It also closed the Biocon Biologics equity sale, launched Inpefa in the UAE, advanced several regulatory submissions including MR-141 and the low-dose estrogen patch, received FDA approval for generic octreotide acetate, and temporarily suspended production at its Nashik, India facility after a February 2026 fire.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $14.7B | — | $736M+ $38M short-term inv. | —$2.3B operating cash flow | report ↗ |
| 2023-FY | $15.4B | — | $994M+ $37M short-term inv. | —$2.8B operating cash flow | report ↗ |
| 2022-FY | $16.2B | — | $1.3B+ $35M short-term inv. | —$3.0B operating cash flow | report ↗ |
| 2021-FY | $17.8B | $751M | $706M+ $38M short-term inv. | —$3.0B operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($1.1M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-09-30 | SIMMONS DAVID S · director | Award / grant (derivative) | 2,117 | $17.72 | $38K | Form 4 |
| 2026-09-30 | Groothuis Leo Frans · director | Award / grant (derivative) | 2,469 | $17.72 | $44K | Form 4 |
| 2026-08-15 | Enrietti Andrew · See Remarks | Option exercise | 25,134 | — | — | Form 4 |
| 2026-08-15 | Enrietti Andrew · See Remarks | Tax withholding | 10,931 | $16.23 | $177K | Form 4 |
| 2026-08-15 | Enrietti Andrew · See Remarks | Option exercise | 999 | — | — | Form 4 |
| 2026-08-15 | Enrietti Andrew · See Remarks | Tax withholding | 435 | $16.23 | $7K | Form 4 |
| 2026-08-15 | Enrietti Andrew · See Remarks | Option exercise (derivative) | 25,134 | — | — | Form 4 |
| 2026-08-15 | Enrietti Andrew · See Remarks | Option exercise (derivative) | 998.364 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 1,006 reporting institutions held 990.2M shares ($12.1B, 86.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 84,359,804 | $1.1B |
| 2 | Davis Selected Advisers | 78,211,191 | $1.1B |
| 3 | VANGUARD CAPITAL MANAGEMENT LLC | 74,716,631 | $1.0B |
| 4 | VANGUARD PORTFOLIO MANAGEMENT LLC | 53,911,237 | $728.3M |
| 5 | STATE STREET CORP | 52,233,699 | $705.7M |
| 6 | DIMENSIONAL FUND ADVISORS LP | 38,310,693 | $517.5M |
| 7 | Rubric Capital Management LP | 33,500,000 | $452.6M |
| 8 | GEODE CAPITAL MANAGEMENT, LLC | 31,846,107 | $429.5M |
| 9 | Invesco Ltd. | 21,968,657 | $296.8M |
| 10 | DEERFIELD MANAGEMENT COMPANY, L.P. | 20,206,170 | $273.0M |
| 11 | AMERIPRISE FINANCIAL INC | 20,014,966 | $270.4M |
| 12 | FMR LLC | 16,588,514 | $224.1M |
| 13 | MORGAN STANLEY | 16,089,939 | $217.4M |
| 14 | Bank of New York Mellon Corp | 14,128,917 | $190.9M |
| 15 | GOLDMAN SACHS GROUP INC | 13,717,622 | $185.3M |